Glucagon‐like peptide ‐1/glucagon receptor agonism associates with reduced metabolic adaptation and higher fat oxidation: A randomized trial
Authors' conclusion
SAR425899 led to reduced selective metabolic adaptation and increased lipid oxidation, which are believed to be beneficial for weight loss and weight-loss maintenance.
Study context
- Population
- Healthy males and females with overweight and obesity (age = 36.5 ± 7.1 years)
- Participants
- 35 males
- Comparison
- GLP-1/glucagon receptor agonist SAR425899 vs placebo, with calorie-reduced diet
- SAR425899n = 17
- Placebon = 18reference
- Primary endpoint
- Change in sleeping metabolic rate (SMR; kcal/day) adjusted for loss of lean and fat mass (metabolic adaptation), by whole-room calorimetry
- Follow-up
- 19 days
Methodological detailsPhase 1b, double-blind, placebo-controlled, two centres, inpatient metabolic wards
- Phase 1b
- Double-blind
- Placebo-controlled
- Two centres
- Inpatient metabolic wards
Primary result
As reported in the abstract
Body composition-adjusted SMR reduction
- Smaller reduction in body composition-adjusted sleeping metabolic rate (SMR) with SAR425899 vs placebo
- SAR425899 vs Placebo: P = 0.002
Further findings
| Outcome | SAR425899 | Placebo | P value |
|---|---|---|---|
| Weight change | −4.83 ± 1.44 kg | −3.68 ± 1.37 kg | P < 0.05 |
- Fat oxidation and ketogenesis · greater increases with SAR425899
- P < 0.05
- Weight change: more loss of weight, fat mass and fat free mass with SAR425899
Weight change
- Greater achieved energy deficit than planned with SAR425899
24-hour energy expenditure
- No smaller reduction with SAR425899 vs placebo
Fat oxidation and ketogenesis
- Increased in both groups
Original publication
Glucagon‐like peptide ‐1/glucagon receptor agonism associates with reduced metabolic adaptation and higher fat oxidation: A randomized trial. Obesity (Silver Spring). Published 25 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →